Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity

Synapse

Volumn 66, Issue 5, 2012, Pages 435-444

  Golembiowska, Krystyna ^a   Kowalska, Magdalena ^a   Bymaster, Frank P ^b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b Euthymics Bioscience Inc   (United States)

Author keywords

Antidepressant; Dopamine; Microdialysis; Norepinephrine; Serotonin; Uptake inhibitor

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; AMITIFADINE; DOPAMINE; HOMOVANILLIC ACID; LACTAM; MONOAMINE; NORADRENALIN; SEROTONIN;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; IN VIVO STUDY; INHIBITION KINETICS; LOCOMOTION; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; STEREOTYPY;

3,4-DIHYDROXYPHENYLACETIC ACID; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; BRAIN; DEPRESSIVE DISORDER, MAJOR; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; HOMOVANILLIC ACID; HYDROXYINDOLEACETIC ACID; MALE; MICRODIALYSIS; MOTOR ACTIVITY; NOREPINEPHRINE; RATS; RATS, WISTAR; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; STEREOTYPED BEHAVIOR;

EID: 84857684977     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21531     Document Type: Article

References (75)

1. Aluisio L, Lord B, Barbier AJ, Fraser IC, Wilson SJ, Boggs J, Dvorak LK, Letavic MA, Maryanoff BE, Carruthers NI, Bonaventure P, Lovenberg TW. 2008. In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor. Eur J Pharmacol 587: 141-146.
2. Arnsten AF. 2009. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: An important role for prefrontal cortex dysfunction. CNS Drugs 23 (Suppl 1): 33-41.
3. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. 2008. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: A randomised, double-blind, placebo-controlled trial. Lancet 372: 1906-1913.
4. Baldwin DS, Papakostas GI. 2006. Symptoms of fatigue and sleepiness in major depressive disorder. J Clin Psychiatry 67 (Suppl 6): 9-15.
5. Baxter LRJr, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, Gerner RH, Sumida RM. 1989. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 46: 243-250.
6. Borsini F, Meli A. 1988. Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology 94: 147-160.
7. Bunin MA, Wightman RM. 1998. Measuring uptake rates in intact tissue. Methods Enzymol 296: 689-707.
8. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW. 2002a. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27: 699-711.
9. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, Wong DT, Perry KW. 2002b. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology 160: 353-361.
10. Carboni E, Tanda GL, Frau R, Di Chiara G. 1990. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: Evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55: 1067-1070.
11. Clayton AH, Montejo AL. 2006. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 67 (Suppl 6): 33-37.
12. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, Bass KI, Donahue RM, Jamerson BD, Metz A. 2002. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 63: 357-366.
13. Daws LC. 2009. Unfaithful neurotransmitter transporters: Focus on serotonin uptake and implications for antidepressant efficacy. Pharmacol Ther 121: 89-99.
14. Di Pietro NC, Seamans JK. 2011. Dopamine and serotonin interactively modulate prefrontal cortex neurons in vitro. Biol Psychiatry 69: 1204-1211.
15. Dunlop BW, Nemeroff CB. 2007. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 64: 327-337.
16. Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, Janowsky A. 1999. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J Pharmacol Exp Ther 289: 877-885.
17. Fava M. 2000. Weight gain and antidepressants. J Clin Psychiatry 61 (Suppl 11): 37-41.
18. Fava M, Graves LM, Benazzi F, Scalia MJ, Iosifescu DV, Alpert JE, Papakostas GI. 2006. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry 67: 1754-1759.
19. Fuller RW, Perry KW, Molloy BB. 1974. Effect of an uptake inhibitor on serotonin metabolism in rat brain: Studies with 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine (Lilly 110140). Life Sci 15: 1161-1171.
20. Fuxe K, Dahlström A, Höistad M, Marcellino D, Jansson A, Rivera A, Diaz-Cabiale Z, Jacobsen K, Tinner-Staines B, Hagman B, Leo G, Staines W, Guidolin D, Kehr J, Genedani S, Belluardo N, Agnati LF. 2007. From the Golgi-Cajal mapping to the transmitter-based characterization of the neuronal networks leading to two modes of brain communication: Wiring and volume transmission. Brain Res Rev 55: 17-54.
21. Gorwood P. 2008. Neurobiological mechanisms of anhedonia. Dialogues Clin Neurosci 10: 291-299.
22. Healy D, McMonagle T. 1997. The enhancement of social functioning as a therapeutic principle in the management of depression. J Psychopharmacol 11 (4 Suppl): S25-S31.
23. Heil SH, Holmes HW, Bickel WK, Higgins ST, Badger GJ, Laws HF, Faries DE. 2002. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 67: 149-156.
24. Jerlhag E, Egecioglu E, Dickson SL, Engel JA. 2010. Ghrelin receptor antagonism attenuates cocaine- and amphetamine-induced locomotor stimulation, accumbal dopamine release, and conditioned place preference. Psychopharmacology 211: 415-422.
25. Kendler KS, Thornton LM, Gardner CO. 2000. Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the "kindling" hypothesis. Am J Psychiatry 157: 1243-1251.
26. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS; National Comorbidity Survey Replication. 2003. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 289: 3095-3105.
27. Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T. 2010. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem 114: 259-270.
28. Lengyel K, Pieschl R, Strong T, Molski T, Mattson G, Lodge NJ, Li YW. 2008. Ex vivo assessment of binding site occupancy of monoamine reuptake inhibitors: Methodology and biological significance. Neuropharmacology 55: 63-70.
29. Li SX, Perry KW, Wong DT. 2002. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 42: 181-190.
30. Liang Y, Richelson E. 2008. Triple reuptake inhibitors: Next generation antidepressant. Primary Psychiatry 15: 50-56.
31. Liang Y, Shaw AM, Boules M, Briody S, Robinson J, Oliveros A, Blazar E, Williams K, Zhang Y, Carlier PR, Richelson E. 2008. Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S, 2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS). J Pharmacol Exp Ther 327: 573-583.
32. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA. 2000. Regional metabolic effects of fluoxetine in major depression: Serial changes and relationship to clinical response. Biol Psychiatry 48: 830-843.
33. McCabe C, Mishor Z, Cowen PJ, Harmer CJ. 2010. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry 67: 439-445.
34. Micheli F, Cavanni P, Arban R, Benedetti R, Bertani B, Bettati M, Bettelini L, Bonanomi G, Braggio S, Checchia A, Davalli S, Di Fabio R, Fazzolari E, Fontana S, Marchioro C, Minick D, Negri M, Oliosi B, Read KD, Sartori I, Tedesco G, Tarsi L, Terreni S, Visentini F, Zocchi A, Zonzini L. 2010. 1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: A new series of potent and selective triple reuptake inhibitors. J Med Chem 53: 2534-2551.
35. Miller EK, Cohen JD. 2001. An integrative theory of prefrontal cortex function. Annu Rev Neurosci 24: 167-202.
36. Moran-Gates T, Zhang K, Baldessarini RJ, Tarazi FI. 2005. Atomoxetine blocks motor hyperactivity in neonatal 6-hydroxydopamine-lesioned rats: Implications for treatment of attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 8: 439-444.
37. Murray CJ, Lopez AD. 1997. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349: 1436-1442.
38. Naranjo CA, Tremblay LK, Busto UE. 2001. The role of the brain reward system in depression. Prog Neuropsychopharmacol Biol Psychiatry 25: 781-823.
39. Negus SS, Mello NK, Blough BE, Baumann MH, Rothman RB. 2007. Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: Studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther 320: 627-636.
40. Nutt DJ, Baldwin DS, Clayton AH, Elgie R, Lecrubier Y, Montejo AL, Papakostas GI, Souery D, Trivedi MH, Tylee A. 2006. Consensus statement and research needs: The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry 67 (Suppl 6): 46-49.
41. Papakostas GI. 2007. Limitations of contemporary antidepressants: Tolerability. J Clin Psychiatry 68 (Suppl 10): 11-17.
42. Papakostas GI, Nutt DJ, Hallett LA, Tucker VL, Krishen A, Fava M. 2006. Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry. 60: 1350-1355.
43. Parker G, Snowdon J, Parker K. 2003. Modelling late-life depression. Int J Geriatr Psychiatry. 18: 1102-1109.
44. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates. New York: Academic Press.
45. Pelizza L, Ferrari A. 2009. Anhedonia in schizophrenia and major depression: State or trait? Ann Gen Psychiatry 8: 22.
46. Perovic S, Müller WE. 1995. Pharmacological profile of hypericum extract. Effect on serotonin uptake by postsynaptic receptors. Arzneimittelforschung 45: 1145-1148.
47. Popik P, Krawczyk M, Golembiowska K, Nowak G, Janowsky A, Skolnick P, Lippa A, Basile AS. 2006. Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102, 677. Cell Mol Neurobiol 26: 857-873.
48. Porsolt RD, Le Pichon M, Jalfre M. 1977. Depression: A new animal model sensitive to antidepressant treatments. Nature 266: 730-732.
49. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA. 1999. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 45: 1085-1098.
50. Rea K, Folgering J, Westerink BH, Cremers TI. 2010. Alpha1-adrenoceptors modulate citalopram-induced serotonin release. Neuropharmacology 58: 962-971.
51. Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM. 2010. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther 88: 69-78.
52. Serretti A, Chiesa A. 2009. Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis. J Clin Psychopharmacol 29: 259-266.
53. Shelton RC, Tomarken AJ. 2001. Can recovery from depression be achieved? Psychiatr Serv 52: 1469-1478.
54. Shen HW, Hagino Y, Kobayashi H, Shinohara-Tanaka K, Ikeda K, Yamamoto H, Yamamoto T, Lesch KP, Murphy DL, Hall FS, Uhl GR, Sora I. 2004. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology 29: 1790-1799.
55. Skolnick P, Basile AS. 2007. Triple reuptake inhibitors ("broad spectrum" antidepressants). CNS Neurol Disord Drug Targets 6: 141-149.
56. Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS. 2003. Antidepressant-like actions of DOV 21, 947: A "triple" reuptake inhibitor. Eur J Pharmacol 461: 99-104.
57. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, Coryell W, Warshaw M, Turvey C, Maser JD, Endicott J. 2000. Multiple recurrences of major depressive disorder. Am J Psychiatry 157: 229-233.
58. Swanson CJ, Perry KW, Koch-Krueger S, Katner J, Svensson KA, Bymaster FP. 2006. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 50: 755-760.
59. Thase ME. 2003. Effectiveness of antidepressants: Comparative remission rates. J Clin Psychiatry 64 (Suppl 2): 3-7.
60. Tizzano JP, Stribling DS, Perez-Tilve D, Strack A, Frassetto A, Chen RZ, Fong TM, Shearman L, Krieter PA, Tschöp MH, Skolnick P, Basile AS. 2008. The triple uptake inhibitor (1R, 5S)-(+)-1-(3, 4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity. J Pharmacol Exp Ther 324: 1111-1126.
61. Tran P, Skolnick P, Czobor P, Huang NY, Bradshaw M, McKinney A, Fava M. 2012. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. J Psychiatr Res 46: 64-71.
62. Tremblay P, Blier P. 2006. Catecholaminergic strategies for the treatment of major depression. Curr Drug Targets 7: 149-158.
63. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M;STAR*D Study Team. 2006a. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 163: 28-40.
64. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ;STAR*D Study Team. 2006b. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354: 1243-1252.
65. Tsuchida R, Kubo M, Kuroda M, Shibasaki Y, Shintani N, Abe M, Köves K, Hashimoto H, Baba A. 2009. An antihyperkinetic action by the serotonin 1A-receptor agonist osemozotan co-administered with psychostimulants or the non-stimulant atomoxetine in mice. J Pharmacol Sci 109: 396-402.
66. Vizi ES, Zsilla G, Caron MG, Kiss JP. 2004. Uptake and release of norepinephrine by serotonergic terminals in norepinephrine transporter knock-out mice: Implications for the action of selective serotonin reuptake inhibitors. J Neurosci 24: 7888-7894.
67. Volkow ND, Swanson JM. 2003. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 160: 1909-1918.
68. Wise RA. 2002. Brain reward circuitry: Insights from unsensed incentives. Neuron 36: 229-240.
69. Wise RA, Bozarth MA. 1987. A psychomotor stimulant theory of addiction. Psychol Rev 94: 469-492.
70. Wong DT, Bymaster FP. 2002. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res 58: 169-222.
71. Wong DT, Bymaster FP, Engleman EA. 1995. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication. Life Sci 57: 411-441.
72. Wultz B, Sagvolden T, Moser EI, Moser MB. 1990. The spontaneously hypertensive rat as an animal model of attention-deficit hyperactivity disorder: Effects of methylphenidate on exploratory behavior. Behav Neural Biol 53: 88-102.
73. Zajecka JM, Albano D. 2004. SNRIs in the management of acute major depressive disorder. J Clin Psychiatry 65 (Suppl 17): 11-18.
74. Zisook S, Rush AJ, Haight BR, Clines DC, Rockett CB. 2006. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry 59: 203-210.
75. Zhou FC, Tao-Cheng JH, Segu L, Patel T, Wang Y. 1998. Serotonin transporters are located on the axons beyond the synaptic junctions: Anatomical and functional evidence. Brain Res 805: 241-254.